KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 71 filers reported holding KALA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $250,000 | +13.1% | 162,134 | +0.6% | 0.00% | – |
| Q4 2021 | $221,000 | -57.5% | 161,131 | -3.4% | 0.00% | – |
| Q3 2021 | $520,000 | -46.0% | 166,749 | -8.2% | 0.00% | – |
| Q2 2021 | $963,000 | -49.8% | 181,653 | -36.2% | 0.00% | -100.0% |
| Q1 2021 | $1,918,000 | +17.9% | 284,639 | +18.7% | 0.00% | 0.0% |
| Q4 2020 | $1,627,000 | +37.4% | 239,869 | +52.0% | 0.00% | – |
| Q3 2020 | $1,184,000 | -57.2% | 157,813 | -40.1% | 0.00% | -100.0% |
| Q2 2020 | $2,767,000 | +74.6% | 263,306 | +46.0% | 0.00% | 0.0% |
| Q1 2020 | $1,585,000 | +144.6% | 180,334 | +2.7% | 0.00% | – |
| Q4 2019 | $648,000 | +72.3% | 175,623 | +77.8% | 0.00% | – |
| Q3 2019 | $376,000 | -62.0% | 98,752 | -36.3% | 0.00% | – |
| Q2 2019 | $989,000 | – | 154,914 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |